Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Certara acquires Simcyp

Simcyp Limited announces its acquisition by Certara, a leading provider of drug discovery and development software and scientific consulting services.

24 Feb 2012

Study underscores power of real-time cell monitoring to dissect pluridimensionality of GPCR signaling

A research team led by Dr. Michel Bouvier at the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal in Quebec, used the Roche xCELLigence SP Instrument to measure changes in cell response following ligand stimulation.

From Roche Sequencing and Life Science 16 Feb 2012

Virginia Tech professor to receive Costa Rica's 2011 National Technology Prize

Pablo Sobrado, assistant professor of biochemistry at Virginia Tech, has been awarded Costa Rica's 2011 National Technology Prize, administered by the Ministry of Science and Technology.

16 Feb 2012

Scripps Research, Brooks partner to develop and commercialize Plate Auditor

Brooks Life Science Systems, a division of Brooks Automation, Inc., a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets, today announced the initiation of a technology development and commercialization partnership with The Scripps Research Institute.

9 Feb 2012

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

8 Feb 2012

BioLineRx, Genoscience and RFS Pharma enter agreement for BL-8030 Hepatitis C treatment

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.

6 Feb 2012

Tennessee Gov. declares February as 'St. Jude Month'

In 1962, St. Jude Children's Research Hospital opened its doors amid an emotionally charged debate regarding how to treat childhood cancer. At that time, few children with the most common form of childhood cancer survived, and many physicians believed treatment was futile. St. Jude physicians and researchers took a radically different approach, and these efforts proved pivotal in changing the way the world treats childhood cancer.

6 Feb 2012

Scientists identify molecular switch that controls ATF2's dual functions

The National Cancer Institute (NCI) estimates that as many as one in 51 men and women will be diagnosed with melanoma-the deadliest form of skin cancer-at some point during their lifetimes. A research team led by Ze'ev Ronai, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) is working to unravel the molecular mechanisms underlying the development and progression of this disease in hopes of improving prevention and treatment strategies

3 Feb 2012

Researchers identify fexinidazole as potential new therapy for visceral leishmaniasis

Researchers at the University of Dundee have identified fexinidazole as a possible, much-needed, new treatment for the parasitic disease visceral leishmaniasis.

3 Feb 2012

Almac introduces NGS data analysis services

Almac's Diagnostics business unit today announced launch of its advanced Next Generation Sequencing (NGS) data analysis services.

2 Feb 2012

USF receives DOD grant for battlefield-related TBI research

The University of South Florida (USF) has received a $1.57 million U.S. Department of Defense grant to conduct translational research on traumatic brain injury and other battlefield related injuries and diseases.

2 Feb 2012

Dana-Farber receives MLSC grant to expand cancer imaging research

The Massachusetts Life Sciences Center has awarded Dana-Farber Cancer Institute a $10 million grant to support the expansion of its pioneering cancer imaging research program.

1 Feb 2012

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012.

31 Jan 2012

Janssen, Orexo to end OX-CLI/OX-ESI research collaboration and license agreement

Orexo AB and Janssen Pharmaceuticals, Inc., formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV, have decided to end their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs and a third, undisclosed Janssen program.

31 Jan 2012

GUMC licenses worldwide rights of 'theranostic' to BioMetrx

Georgetown University Medical Center (GUMC) has licensed worldwide rights of a potential novel cancer therapy and diagnostic, or "theranostic," to BioMetrx, LLC. The agent was invented by two Georgetown researchers.

25 Jan 2012

Roche proposes to acquire Illumina for $44.50 per share

Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis.

From Roche Sequencing and Life Science 24 Jan 2012

BJALCF receives $1 million in grants for 2012 Lung Cancer Research

Just two months shy of marking its 7-year anniversary, BJALCF announced today that it has awarded over $1 million in grants for 2012 Lung Cancer Research. BJALCF has made a promise to the Lung Cancer Community to fund only immediate results-oriented projects or programs promising to catalyze progress through early detection, genetic testing, drug discovery and patient-focused outcomes.

17 Jan 2012

UI chemists debunk misconception about amphotericin

With one simple experiment, University of Illinois chemists have debunked a widely held misconception about an often-prescribed drug.

17 Jan 2012

IBM's non-contact, microfluidic, silicon probe minimizes patient discomfort

IBM scientists have developed a flexible, non-contact microfluidic probe made from silicon that can aid researchers and pathologists to investigate critical tissue samples accurately for drug discovery and disease diagnostics.

13 Jan 2012

UCSF, Sanofi enter $3.1 million collaboration to identify diabetes drug targets

The University of California, San Francisco has signed an alliance with international pharmaceutical company Sanofi to share expertise in diabetes research and identify drug targets that could lead to new therapies for both type 1 and type 2 diabetes.

11 Jan 2012